IVD MEDICAL (01931) surged more than 11%. As of the time of writing, the stock was up 11.25%, trading at HK$1.78, with a turnover of HK$20.59 million.

On the news front, on the evening of January 27, IVD MEDICAL announced that its subsidiary, Shenzhen Tanhua Biotechnology Co., Ltd. ("Tanhua Biotechnology"), has successfully developed a dual-platform detection solution for the Nipah virus, possessing full-process technical support capabilities from rapid screening to precise traceability.

The dual-platform refers to the intelligent fluorescent PCR rapid detection platform and the high-throughput sequencing and intelligent analysis platform.

The announcement stated that the rapid implementation of this Nipah virus detection capability is not only a reflection of Tanhua Biotechnology's technical strength but also a crucial component in the advancement of IVD MEDICAL's overall AI healthcare strategy.

With the company's acquisition of Chuangye Huikang Technology Co., Ltd. (Stock Code: 300451.SZ) progressing steadily (relevant procedures are advancing in an orderly manner), the Group is accelerating the construction of a next-generation public health prevention and control paradigm centered on "AI Early Warning + Rapid Diagnosis + Ecological Synergy".